US 12,440,568 B2
Material and method for treating internal cavities
Asher Holzer, Raanana (IL); Dorit Daniel, Raanana (IL); Michael Mullerad, Tel Aviv (IL); Jaime De La Zerda, Haifa (IL); Uri Shpolansky, Pardes Hana (IL); Nadav Malchi, Pardes Hanna-Karkur (IL); Yosh Dollberg, Raanana (IL); Dor Tal, Hadera (IL); and Yossi Yavin, Mikhmoret (IL)
Assigned to UroGen Pharma Ltd., Ra'anana (IL)
Filed by UroGen Pharma Ltd., Ra'anana (IL)
Filed on Feb. 28, 2025, as Appl. No. 19/066,754.
Application 18/129,497 is a division of application No. 17/566,882, filed on Dec. 31, 2021, abandoned.
Application 19/066,754 is a continuation of application No. 18/625,862, filed on Apr. 3, 2024, granted, now 12,268,745.
Application 18/625,862 is a continuation of application No. 18/129,497, filed on Mar. 31, 2023, abandoned.
Application 17/566,882 is a continuation of application No. 16/518,511, filed on Jul. 22, 2019, abandoned.
Application 16/518,511 is a continuation of application No. 14/054,731, filed on Oct. 15, 2013, granted, now 10,471,150, issued on Nov. 12, 2019.
Application 14/054,731 is a continuation in part of application No. 13/553,198, filed on Jul. 19, 2012, granted, now 9,040,074, issued on May 26, 2015.
Application 13/553,198 is a continuation in part of application No. PCT/IL2011/000069, filed on Jan. 20, 2011.
Claims priority of provisional application 61/296,589, filed on Jan. 20, 2010.
Prior Publication US 2025/0195665 A1, Jun. 19, 2025
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/07 (2006.01); A61K 9/00 (2006.01); A61K 9/06 (2006.01); A61K 31/122 (2006.01); A61K 31/167 (2006.01); A61K 31/192 (2006.01); A61K 31/337 (2006.01); A61K 31/397 (2006.01); A61K 31/407 (2006.01); A61K 31/59 (2006.01); A61K 31/704 (2006.01); A61K 31/7068 (2006.01); A61K 38/48 (2006.01); A61K 47/10 (2017.01); A61K 47/34 (2017.01); A61K 47/38 (2006.01)
CPC A61K 47/34 (2013.01) [A61K 9/0034 (2013.01); A61K 9/06 (2013.01); A61K 31/07 (2013.01); A61K 31/122 (2013.01); A61K 31/167 (2013.01); A61K 31/192 (2013.01); A61K 31/337 (2013.01); A61K 31/397 (2013.01); A61K 31/407 (2013.01); A61K 31/59 (2013.01); A61K 31/704 (2013.01); A61K 31/7068 (2013.01); A61K 38/4893 (2013.01); A61K 47/10 (2013.01); A61K 47/38 (2013.01)] 10 Claims
 
1. A method of treating superficial bladder cancer comprising:
(a) preparing a composition by incorporating an effective amount of mitomycin C and an accompanying excipient into a thermoreversible hydrogel, the accompanying excipient being mannitol; and
(b) administering the composition to the urinary bladder of a human in need of such treatment,
wherein the thermoreversible hydrogel comprises:
(i) 23% to 27% (w/w) poloxamer 407;
(ii) 0.15% to 0.2% (w/w) hydroxypropylmethylcellulose;
(iii) 0.5% to 1.8% (w/w) PEG-400; and
(iv) water.